Skip to content

Respiratory, CVRM & LIVEr

Fibroproliferative and cardiometabolic disorders are estimated to contribute to 45% of deaths*. The magnitude of this unmet clinical need is resulting in intense efforts to develop novel therapeutics.


The Respiratory, CVRM & Liver Event Series' mission is to enable drug developers to eradicate these types of diseases and provide a better standard of care for patients.